Kala Pharmaceuticals Inc (OQ:KALA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 100 Beaver St Ste 201
WALTHAM MA 02453-8425
Tel: N/A
Website: kalarx.com
IR: See website
<
Key People
Mark T. Iwicki
Chairman of the Board, President, Chief Executive Officer
Mary Reumuth
Chief Financial Officer, Treasurer
Todd M. Bazemore
Chief Operating Officer
Hongming Chen
Chief Scientific Officer
Eric L. Trachtenberg
General Counsel, Corporate Secretary
Kim Brazzell
Chief Medical Officer
Business Overview
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company's initial focus is on the treatment of eye diseases. The Company's product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company's product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Financial Overview
For the nine months ended 30 September 2018, Kala Pharmaceuticals Inc revenues was not reported. Net loss increased 34% to $41.5M. Higher net loss reflects General and administrative - Balancing v increase from $4.3M to $16.7M (expense), Stock-Based Compensation increase from $1.3M to $4.4M (expense), Stock-Based Compensation increase from $749K to $2.1M (expense).
Employees: 37 as of Dec 31, 2017
Reporting Currency: U.S. Dollars
Enterprise value: $163.54M as of Sep 30, 2018
Annual revenue (TTM): $0.00M as of Sep 30, 2018
EBITDA (TTM): -$51.69M as of Sep 30, 2018
Net annual income (TTM): -$52.81M as of Sep 30, 2018
Free cash flow (TTM): -$45.65M as of Sep 30, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 33,795,656 as of Nov 6, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization